Experiencia de un hospital universitario en el manejo de púrpura trombótico trombocitopénico-microangiopatía trombótica no inmune refractaria o en recaída tratado con rituximab: Report of eight cases

• Mauricio Sarmiento Maldonado ^[1] ; Pablo Bertín Cortés-Monroy ^[1] ; Pablo Lira Vergara ^[1] ; María Alejandra Rodríguez Ingles ^[1] ; María José García Rodríguez ^[1] ; Pablo Ramírez Villanueva ^[1] ; Mauricio Ocqueteau Tachini ^[1]
  1. [1] Pontificia Universidad Católica de Chile

     Pontificia Universidad Católica de Chile

     Santiago, Chile

     
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 143, Nº. 6, 2015, págs. 809-811
• Idioma: español
• Títulos paralelos:
  • Treatment of thrombotic thrombocytopenic purpura with rituximab
• Enlaces
  • Texto completo
• Resumen

  • Thrombotic thrombocytopenic purpura, an immune/non-immune thrombotic microangiopathy (TTP/TMA) is associated with high morbidity and mortality, even with appropriate treatment. In patients refractory to standard treatment with plasmapheresis there is no certainty about the best therapeutic strategy. This report shows our experience in eight refractory patients who survived after treatment with rituximab.